Page last updated: 2024-11-13
5'-hydroxypiroxicam
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
5'-hydroxypiroxicam: metabolite of pyroxicam; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 54676301 |
| CHEMBL ID | 1217 |
| CHEBI ID | 175413 |
| MeSH ID | M0145414 |
Synonyms (23)
| Synonym |
|---|
| unii-xbg963w8bl |
| xbg963w8bl , |
| 5-hydroxypiroxicam |
| 2h-1,2-benzothiazine-3-carboxamide, 4-hydroxy-n-(5-hydroxy-2-pyridinyl)-2-methyl-, 1,1-dioxide |
| CHEBI:175413 |
| 4-hydroxy-n-(5-hydroxypyridin-2-yl)-2-methyl-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide |
| 77459-78-0 |
| 5'-hydroxypiroxicam |
| hydroxy piroxicam metabolite |
| CHEMBL1217 |
| DTXSID50228171 |
| 4-hydroxy-n-(5-hydroxypyridin-2-yl)-2-methyl-1,1-dioxo-2h-1$l^{6},2-benzothiazine-3-carboxamide |
| 5'-hydroxypiroxicam, vetranal(tm), analytical standard |
| 76066-11-0 |
| 5 inverted exclamation mark -hydroxypiroxicam |
| E72292 |
| 2h-1,2-benzothiazine-3-carboxamide,4-hydroxy-n-(5-hydroxy-2-pyridinyl)-2-methyl-, 1,1-dioxide |
| piroxicam-5'-hydroxy |
| 2h-1,2-benzothiazine-3-carboxamide, 4-hydroxy-n-(5-hydroxy-2-pyridinyl)-2-methyl-, 1,1-dioxide; 5'-hydroxypiroxicam |
| 5'-hydroxy-piroxicam |
| piroxicam-5'-hydroxy 100 microg/ml in acetonitrile |
| WS-03101 |
| 4-hydroxy-n-(5-hydroxypyridin-2-yl)-2-methyl-2h-benzo[e][1,2]thiazine-3-carboxamide1,1-dioxide |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "We compared the endoscopic effects and pharmacokinetic profiles of an experimental buccal formulation of piroxicam to oral capsules in an attempt to determine whether nonsteroidal antiinflammatory drug-induced gastropathy is due to a local or systemic effect." | ( A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation. Brater, DC; Figueroa, N; Greene, P; Mueller, BA; Rex, DK, 1992) | 0.28 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Upper endoscopies were performed at the baseline and at the end of each 2-week dosing arm of the study." | ( A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation. Brater, DC; Figueroa, N; Greene, P; Mueller, BA; Rex, DK, 1992) | 0.28 |
| " creatinine clearance 88 +/- 13 ml min-1), and (3) elderly patients with renal insufficiency (creatinine clearance 60 +/- 10 ml min-1) following the administration of piroxicam 20 mg as a single dose and after chronic dosing of 20 mg once daily for 4 weeks." | ( The pharmacokinetics of piroxicam in elderly persons with and without renal impairment. Brater, DC; Figueroa, NL; Hall, SD; Rudy, AC, 1994) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| benzothiazine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID183497 | Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 10 mg/kg. | 1981 | Journal of medicinal chemistry, Jan, Volume: 24, Issue:1 | Synthesis and antiinflammatory activity of metabolites of piroxicam. |
| AID183500 | Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 33 mg/kg. | 1981 | Journal of medicinal chemistry, Jan, Volume: 24, Issue:1 | Synthesis and antiinflammatory activity of metabolites of piroxicam. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.78
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.78) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (8.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||